

**Generation of
6*H*-benzo[*f*]cyclopenta[*d*][1,2]thiazepine 5,5-dioxides
via a palladium-catalyzed reaction of
2-(2-alkynyl)benzenesulfonamide**

Huanhuan Wang,^a Yong Luo,^a Xiufeng Hou,^{*,a} and Jie Wu^{*,ab}

^a Department of Chemistry, Fudan University, 220 Handan Road, Shanghai 200433, China

^b State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry,

Chinese Academy of Sciences, 354 Fenglin Road, Shanghai 200032, China

jie_wu@fudan.edu.cn


Supporting Information

1. General experimental methods (S2).
2. General experimental procedure and characterization data (S2-S10).
3. ¹H and ¹³C NMR spectra of compound 3 (S11-S40).


General Materials and Methods:

Unless otherwise stated, all commercial reagents were used as received. All solvents were dried and distilled according to standard procedures. Flash column chromatography was performed using silica gel (60-Å pore size, 32–63 µm, standard grade). Analytical thin-layer chromatography was performed using glass plates pre-coated with 0.25 mm 230–400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Thin layer chromatography plates were visualized by exposure to ultraviolet light. Organic solutions were concentrated on rotary evaporators at ~20 Torr at 25–35°C. Nuclear magnetic resonance (NMR) spectra are recorded in parts per million from internal tetramethylsilane on the δ scale. ^1H and ^{13}C NMR spectra were recorded in CDCl_3 on a Bruker DRX-400 spectrometer operating at 400 MHz and 100 MHz, respectively. All chemical shift values are quoted in ppm and coupling constants quoted in Hz. High resolution mass spectrometry (HRMS) spectra were obtained on a micrOTOF II Instrument.

*General procedure of the synthesis of 6H-benzo[f]cyclopenta[d][1,2]thiazepine 5,5-dioxides **3** via a palladium-catalyzed reaction of 2-(2-alkynyl)benzenesulfonamide **1** with 2-alkynylvinyl bromide **2***




2-(2-Alkynyl)benzenesulfonamide **1** (0.30 mmol) was added to a mixture of $\text{Pd}(\text{OAc})_2$ (5 mol%), DPPP (5 mol %), K_2CO_3 (0.60 mmol), and 2-alkynylvinyl bromide **2** (0.36 mmol) in 1,4-dioxane (2.0 mL). The mixture was stirred under 100 °C. After completion of the reaction as indicated by TLC (~12 hours), the mixture was cooled and diluted by EtOAc (10 mL), washed with saturated brine (2×10 mL), and dried by anhydrous Na_2SO_4 . Evaporation of the solvent followed by purification on silica gel provided the product **3**.




6-Methyl-7,10-diphenyl-8,9-dipropyl-6*H*-benzo[*f*]cyclopenta[*d*][1,2]thiazepine


5,5-dioxide (**3a**): Dark red solid; ¹H NMR (400 MHz, CDCl₃) δ 0.43 (t, *J* = 7.3 Hz, 3H), 0.73 (t, *J* = 6.9 Hz, 3H), 1.13-1.26 (m, 4H), 1.43-1.56 (m, 1H), 1.87-1.92 (m, 1H), 2.16-2.24 (m, 1H), 2.29-2.36 (m, 2H), 2.68 (s, 3H), 7.02 (d, *J* = 7.8 Hz, 2H), 7.09 (t, *J* = 7.8 Hz, 1H), 7.18-7.25 (m, 4H), 7.39-7.44 (m, 3H), 7.50-7.56 (m, 2H), 7.77 (d, *J* = 6.4 Hz, 1H), 7.90 (d, *J* = 7.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 14.2, 14.5, 23.5, 25.5, 28.5, 29.0, 36.9, 125.3, 126.3, 127.0, 127.6, 128.3, 128.5, 128.8, 130.0, 130.6, 131.5, 133.2, 133.7, 134.0, 136.4, 136.0, 137.8, 142.6, 146.1, 146.5; HRMS (ESI) calcd for C₃₁H₃₁NO₂S: 504.1968 (M + Na⁺), found: 504.1970.




2-Methoxy-6-methyl-7,10-diphenyl-8,9-dipropyl-6*H*-benzo[*f*]cyclopenta[*d*][1,2]thiazepine 5,5-dioxide (**3b**): Dark red solid; ¹H NMR (400 MHz, CDCl₃) δ 0.43 (t, *J* = 6.9 Hz, 3H), 0.73 (t, *J* = 7.3 Hz, 3H), 1.14-1.27 (m, 4H), 1.48-1.53 (m, 1H), 1.91-1.96 (m, 1H), 2.20-2.26 (m, 1H), 2.30-2.36 (m, 1H), 2.70 (s, 3H), 3.25 (s, 3H), 6.50 (s, 1H), 6.71 (d, *J* = 8.2 Hz, 2H), 7.26-7.54 (m, 9H), 7.80 (d, *J* = 8.7 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 14.3, 14.5, 23.6, 25.6, 28.5, 29.0, 36.9, 55.1, 113.6, 116.7, 126.9, 127.6, 128.2, 128.3, 128.7, 128.8, 130.1, 130.6, 132.8, 133.7, 134.1, 135.8, 136.5, 138.4, 142.3, 146.0, 147.1, 161.6; HRMS (ESI) calcd for C₃₂H₃₃NO₃S: 534.2073 (M + Na⁺), found: 534.2077.




2,6-Dimethyl-7,10-diphenyl-8,9-dipropyl-6*H*-benzo[*f*]cyclopenta[*d*][1,2]thiazepine 5,5-dioxide (**3c**): Dark red solid; ¹H NMR (400 MHz, CDCl₃) δ 0.42 (t, *J* = 7.3 Hz, 3H), 0.72 (t, *J* = 7.3 Hz, 3H), 1.11-1.27 (m, 4H), 1.47-1.52 (m, 1H), 1.87-1.93 (m, 1H), 1.97 (s, 3H), 2.18-2.26 (m, 1H), 2.29-2.36 (m, 1H), 2.67 (s, 3H), 6.78 (s, 1H), 6.99 (d, *J* = 7.8 Hz, 2H), 7.23-7.52 (m, 9H), 7.77 (d, *J* = 7.8 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 14.2, 14.5, 21.3, 23.6, 25.5, 28.5, 29.0, 36.8, 126.2, 126.4, 126.9, 127.6, 128.2, 128.4, 128.8, 130.0, 130.5, 133.2, 133.6, 133.7, 133.9, 134.4, 136.5, 138.0, 142.0, 142.5, 145.9, 146.5; HRMS (ESI) calcd for C₃₂H₃₃NO₂S: 518.2124 (M + Na⁺), found: 518.2142.




2-Chloro-6-methyl-7,10-diphenyl-8,9-dipropyl-6*H*-benzo[*f*]cyclopenta[*d*][1,2]thiazepine 5,5-dioxide (**3d**): Dark red solid; ¹H NMR (400 MHz, CDCl₃) δ 0.43 (t, *J* = 7.3 Hz, 3H), 0.74 (t, *J* = 7.3 Hz, 3H), 1.10-1.29 (m, 4H), 1.48-1.54 (m, 1H), 1.89-1.94 (m, 1H), 2.18-2.27 (m, 1H), 2.28-2.36 (m, 1H), 2.69 (s, 3H), 6.94 (s, 1H), 7.14 (d, *J* = 8.2 Hz, 2H), 7.30 (d, *J* = 6.4 Hz, 2H), 7.40-7.41 (m, 3H), 7.52-7.54 (m, 2H), 7.74-7.76 (m, 1H), 7.81 (d, *J* = 8.7 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 14.2, 14.5, 23.5, 25.5, 28.4, 29.0, 36.9, 125.6, 126.1, 127.4, 127.7, 128.4, 128.7, 128.9, 129.9, 130.7, 133.1, 133.3, 133.7, 134.6, 134.8, 135.6, 136.1, 137.2, 137.8, 142.7, 146.7, 147.3; HRMS (ESI) calcd for C₃₁H₃₀ClNO₂S: 538.1578 (M + Na⁺), found: 538.1569.




10-(4-Chlorophenyl)-2,6-dimethyl-7-phenyl-8,9-dipropyl-6*H*-benzo[*f*]cyclopenta[*d*][1,2]thiazepine 5,5-dioxide (**3e**): Dark red solid; ^1H NMR (400 MHz, CDCl_3) δ 0.42 (t, $J = 6.9$ Hz, 3H), 0.74 (t, $J = 7.3$ Hz, 3H), 1.09-1.25 (m, 4H), 1.42-1.53 (m, 1H), 1.85-1.92 (m, 1H), 2.03 (s, 3H), 2.17-2.24 (m, 1H), 2.26-2.34 (m, 1H), 2.67 (s, 3H), 6.78 (s, 1H), 7.02 (d, $J = 7.8$ Hz, 2H), 7.25-7.39 (m, 5H), 7.49-7.54 (m, 2H), 7.74-7.79 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.2, 14.5, 21.4, 23.6, 25.5, 28.5, 29.0, 36.9, 126.4, 126.5, 128.0, 128.3, 128.6, 128.9, 130.0, 130.6, 132.7, 133.4, 133.7, 133.9, 134.0, 134.3, 136.3, 136.6, 141.9, 142.2, 144.3, 147.1; HRMS (ESI) calcd for $\text{C}_{32}\text{H}_{32}\text{ClNO}_2\text{S}$: 552.1734 ($\text{M} + \text{Na}^+$), found: 552.1734.







10-Cyclopropyl-2,6-dimethyl-7-phenyl-8,9-dipropyl-6H-benzo[f]cyclopenta[d][1,2]thiazepine 5,5-dioxide (**3g**): Dark red solid; ^1H NMR (400 MHz, CDCl_3) δ -1.20- -0.15 (m, 1H), 0.37 (t, $J = 7.3$ Hz, 3H), 0.40-0.45 (m, 1H), 0.60-0.66 (m, 1H), 0.92-1.77 (m, 6H), 1.47-1.54 (m, 2H), 1.66-1.80 (m, 3H), 2.32-2.40 (m, 1H), 2.45 (s, 3H), 2.50-2.58 (m, 1H), 2.60 (s, 3H), 7.16 (d, $J = 7.8$ Hz, 2H), 7.33-7.36 (m, 2H), 7.47 (d, $J = 6.9$ Hz, 2H), 7.65-7.69 (m, 2H), 7.8 (d, $J = 7.8$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 7.8, 10.1, 10.5, 14.1, 14.8, 21.7, 24.0, 25.3, 28.5, 28.8, 36.6, 126.1, 126.4, 127.3, 128.0, 128.8, 130.0, 130.1, 132.4, 133.0, 133.3, 133.4, 134.1, 136.8, 141.7, 144.5, 144.7, 146.0; HRMS (ESI) calcd for $\text{C}_{29}\text{H}_{33}\text{NO}_2\text{S}$: 482.2124 ($\text{M} + \text{Na}^+$), found: 482.2132.




10-Butyl-6-methyl-7-phenyl-8,9-dipropyl-6H-benzo[f]cyclopenta[d][1,2]thiazepine 5,5-dioxide (**3h**): Dark red oil; ^1H NMR (400 MHz, CDCl_3) δ 0.39 (t, $J = 6.9$ Hz, 3H) 0.90 (t, $J = 7.3$ Hz, 3H), 0.98 (t, $J = 7.3$ Hz, 3H), 1.05-1.12 (m, 2H), 1.36-1.42 (m, 2H), 1.49-1.58 (m, 5H), 1.76-1.82 (m, 1H), 2.30 (t, $J = 7.8$ Hz, 2H), 2.44-2.49 (m, 2H), 2.61 (s, 3H), 7.34-7.36 (m, 3H), 7.47-7.60 (m, 4H), 7.71 (d, $J = 6.0$ Hz, 1H), 7.96 (d, $J = 8.4$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.7, 14.0, 14.7, 22.8, 24.2, 25.2, 26.9, 28.3, 28.7, 32.3, 36.4, 125.5, 126.6, 126.7, 127.9, 128.6, 129.8, 130.1, 131.2, 132.0, 133.3, 133.4, 133.7, 134.3, 136.3, 136.5, 142.8, 144.0, 146.1; HRMS (ESI) calcd for $\text{C}_{29}\text{H}_{35}\text{NO}_2\text{S}$: 500.2020 ($\text{M} + \text{K}^+$), found: 500.2001.



10-(4-Fluorophenyl)-6-methyl-7-phenyl-8,9-dipropyl-6*H*-benzo[*f*]cyclopenta[*d*][1,2]thiazepine 5,5-dioxide (**3i**): Dark red solid; ^1H NMR (400 MHz, CDCl_3) δ 0.42 (t, $J = 6.9$ Hz, 3H), 0.73 (t, $J = 6.8$ Hz, 3H), 1.12-1.25 (m, 4H), 1.47-1.54 (m, 1H), 1.86-1.90 (m, 1H), 2.03 (s, 3H), 2.20-2.24 (m, 1H), 2.28-2.34 (m, 1H), 2.68 (s, 3H), 7.00 (d, $J = 7.8$ Hz, 2H), 7.12 (t, $J = 7.8$ Hz, 2H), 7.22 (t, $J = 7.3$ Hz, 2H), 7.36-7.55 (m, 5H), 7.76 (d, $J = 5.5$ Hz, 1H), 7.90 (d, $J = 7.8$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.2, 14.5, 23.5, 25.5, 28.6, 29.0, 36.9, 115.5 (d, $^2J_{\text{CF}} = 21.0$ Hz); 125.7, 126.4, 127.8, 128.3, 128.9, 130.0, 130.7, 131.5, 131.7, 133.0, 133.5, 133.6, 133.8 (d, $^3J_{\text{CF}} = 8.6$ Hz), 136.3, 136.7, 142.2, 144.8, 146.8, 162.0 (d, $^1J_{\text{CF}} = 245.0$ Hz); HRMS (ESI) calcd for $\text{C}_{31}\text{H}_{30}\text{FNO}_2\text{S}$: 522.1873 ($\text{M} + \text{Na}^+$), found: 522.1874.




6-Methyl-7-phenyl-8,9-dipropyl-10-(*p*-tolyl)-6*H*-benzo[*f*]cyclopenta[*d*][1,2]thiazepine 5,5-dioxide (**3j**): Dark red solid; ^1H NMR (400 MHz, CDCl_3) δ 0.43 (t, $J = 7.4$ Hz, 3H), 0.74 (t, $J = 7.3$ Hz, 3H), 1.12-1.27 (m, 4H), 1.49-1.56 (m, 1H), 1.87-1.95 (m, 1H), 2.18-2.24 (m, 1H), 2.30-2.35 (m, 4H), 2.67 (s, 3H), 7.05-7.12 (m, 5H), 7.20 (t, $J = 7.8$ Hz, 2H), 7.37-7.44 (m, 2H), 7.76-7.54 (m, 2H), 7.77 (d, $J = 6.0$ Hz, 1H), 7.90 (d, $J = 7.8$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.3, 14.6, 21.4, 23.6, 25.5, 28.5, 29.0, 36.9, 125.4, 126.3, 127.4, 128.2, 128.8, 129.2, 130.0, 130.5, 131.6, 133.4, 133.7, 134.2, 134.7, 136.4, 136.5, 136.6, 142.8, 146.1, 146.2; HRMS (ESI) calcd for $\text{C}_{32}\text{H}_{33}\text{NO}_2\text{S}$: 518.2124 ($\text{M} + \text{Na}^+$), found: 518.2117.




8,9-Diethyl-6-methyl-7,10-diphenyl-6*H*-benzo[*f*]cyclopenta[*d*][1,2]thiazepine

5,5-dioxide (**3k**): Dark red solid; ¹H NMR (400 MHz, CDCl₃) δ 0.70 (t, *J* = 7.4 Hz, 3H), 0.80 (t, *J* = 6.9 Hz, 3H), 1.60-1.65 (m, 1H), 1.95-2.00 (m, 1H), 2.26-2.38 (m, 2H), 2.68 (s, 3H), 7.02 (d, *J* = 7.8 Hz, 2H), 7.09 (t, *J* = 7.3 Hz, 1H), 7.18-7.25 (m, 4H), 7.38-7.44 (m, 3H), 7.51 (d, *J* = 7.3 Hz, 2H), 7.79 (d, *J* = 7.8 Hz, 1H), 7.90 (d, *J* = 7.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 14.8, 16.7, 19.3, 19.6, 36.9, 125.6, 126.3, 127.0, 127.6, 128.2, 128.5, 128.8, 129.9, 130.6, 131.6, 132.9, 133.6, 133.7, 134.0, 134.9, 136.5, 137.7, 143.8, 146.1, 146.4; HRMS (ESI) calcd for C₂₉H₂₇NO₂S: 476.1655 (M + Na⁺), found: 476.1655.




6-Benzyl-7,10-diphenyl-8,9-dipropyl-6*H*-benzo[*f*]cyclopenta[*d*][1,2]thiazepine


5,5-dioxide (**3l**): Dark red solid; ¹H NMR (400 MHz, CDCl₃) δ 0.43 (t, *J* = 7.3 Hz, 3H), 0.73 (t, *J* = 6.8 Hz, 3H), 1.13-1.28 (m, 4H), 1.42-1.49 (m, 1H), 1.84-1.91 (m, 1H), 2.18-2.24 (m, 1H), 2.29-2.38 (m, 1H), 4.31 (d, *J* = 16.0 Hz, 2H), 4.82 (d, *J* = 16.0 Hz, 2H), 6.45 (d, *J* = 7.8, 2), 6.80 (t, *J* = 6.8 Hz, 2H), 6.86-6.91 (m, 5H), 7.22-7.26 (m, 2H), 7.32-7.33 (m, 3H), 7.50-7.55 (m, 3H), 7.77 (d, *J* = 6.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 14.3, 14.6, 23.6, 25.6, 28.5, 29.1, 53.3, 125.5, 126.9, 127.2, 127.8, 127.9, 128.2, 128.3, 128.4, 128.6, 130.0, 130.4, 131.1, 133.2, 133.5, 133.7, 133.8, 133.9, 135.3, 136.0, 137.9, 139.2, 142.3, 145.7, 146.1; HRMS (ESI) calcd for C₃₇H₃₅NO₂S: 580.2281 (M + Na⁺), found: 580.2281.



7-(4-Chlorophenyl)-6-methyl-10-phenyl-8,9-dipropyl-6*H*-benzo[*f*]cyclopenta[*d*][1,2]thiazepine 5,5-dioxide (**3m**): Dark red solid; ^1H NMR (400 MHz, CDCl_3) δ 0.47 (t, J = 6.9 Hz, 3H), 0.72 (t, J = 7.3 Hz, 3H), 1.11-1.28 (m, 4H), 1.51-1.59 (m, 1H), 1.91-1.97 (m, 1H), 2.18-2.24 (m, 1H), 2.28-2.34 (m, 1H), 2.66 (s, 3H), 7.00 (d, J = 7.8 Hz, 2H), 7.09 (t, J = 7.8 Hz, 1H), 7.18-7.38 (m, 7H), 7.52 (d, J = 8.2 Hz, 1H), 7.71 (d, J = 8.2 Hz, 1H), 7.89 (d, J = 7.8 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.2, 14.5, 23.5, 25.4, 28.5, 29.0, 36.9, 125.7, 126.4, 127.1, 127.6, 128.6, 129.2, 131.3, 131.6, 133.2, 133.6, 133.7, 133.8, 134.8, 134.9, 136.4, 136.9, 137.6, 143.2, 144.9, 146.4; HRMS (ESI) calcd for $\text{C}_{31}\text{H}_{30}\text{ClNO}_2\text{S}$: 538.1578 ($\text{M} + \text{Na}^+$), found: 538.1572.



6-Methyl-10-phenyl-8,9-dipropyl-7-(*p*-tolyl)-6*H*-benzo[*f*]cyclopenta[*d*][1,2]thiazepine 5,5-dioxide (**3n**): Dark red solid; ^1H NMR (400 MHz, CDCl_3) δ 0.45 (t, J = 6.8 Hz, 3H), 0.73 (t, J = 7.3 Hz, 3H), 1.13-1.27 (m, 4H), 1.55-1.61 (m, 1H), 1.90-1.98 (m, 1H), 2.19-2.26 (m, 1H), 2.30-2.38 (m, 1H), 2.45 (s, 3H), 2.69 (s, 3H), 7.01 (d, J = 7.8 Hz, 2H), 7.08 (t, J = 7.4 Hz, 1H), 7.14-7.26 (m, 4H), 7.31-7.36 (m, 3H), 7.65 (d, J = 7.8 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.2, 14.5, 21.6, 23.6, 25.5, 28.5, 29.0, 37.0, 125.4, 126.3, 126.9, 127.5, 128.5, 128.9, 129.6, 129.9, 131.5, 132.9, 133.5, 133.7, 133.8, 134.1, 136.6, 138.0, 141.0, 142.3, 145.8, 146.9; HRMS (ESI) calcd for $\text{C}_{32}\text{H}_{33}\text{NO}_2\text{S}$: 518.2124 ($\text{M} + \text{Na}^+$), found: 518.2127.



7-(4-Methoxyphenyl)-2,6-dimethyl-10-phenyl-8,9-dipropyl-6*H*-benzo[*f*]cyclopenta[*d*][1,2]thiazepine 5,5-dioxide (**3o**): Dark red solid; ^1H NMR (400 MHz, CDCl_3) δ 0.47 (t, $J = 6.8$ Hz, 3H), 0.73 (t, $J = 7.3$ Hz, 3H), 1.12-1.25 (m, 4H), 1.56-1.63 (m, 1H), 1.96-2.22 (m, 4H), 2.20-2.26 (m, 1H), 2.30-2.36 (m, 1H), 2.68 (s, 3H), 6.77 (s, 1H), 6.89 (d, $J = 8.2$ Hz, 1H), 6.98 (d, $J = 7.8$ Hz, 1H), 7.05 (d, $J = 8.2$ Hz, 1H), 7.23-7.35 (m, 6H), 7.68 (d, $J = 8.2$ Hz, 1H), 7.77 (d, $J = 7.8$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.3, 14.6, 21.3, 23.7, 25.4, 28.5, 29.0, 37.0, 55.6, 113.4, 114.6, 126.1, 126.4, 126.8, 127.5, 128.3, 128.6, 130.2, 131.5, 132.5, 133.7, 133.8, 134.3, 135.6, 138.1, 141.9, 142.0, 145.4, 146.8; HRMS (ESI) calcd for $\text{C}_{33}\text{H}_{35}\text{NO}_3\text{S}$: 548.2230 (M + Na^+), found: 548.2230.

